Brief: CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China
10/12/2021 12:06
Dec 10 (Reuters) - CASI Pharmaceuticals, Inc. CASI.O :
* CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL
FOR
CLINICAL STUDY OF BI-1206 IN NHL IN CHINA
* CASI PHARMACEUTICALS INC - NMPA APPROVED BI-1206 CTA A
NOVEL
ANTI-FCΓRIIB
* CASI PHARMACEUTICALS INC - TRIALS EXPECTED TO ENROLL
PATIENTS
STARTING IN 1H 2022
Source text for Eikon: ID:nPn2dK88ma
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary